Free Trial

Entrada Therapeutics (TRDA) News Today

Entrada Therapeutics logo
$7.50 -0.12 (-1.57%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$7.50 0.00 (-0.07%)
As of 05/23/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TRDA Latest News

Entrada Therapeutics, Inc. stock logo
Q2 EPS Estimate for Entrada Therapeutics Raised by Analyst
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - HC Wainwright upped their Q2 2025 EPS estimates for Entrada Therapeutics in a research note issued on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.98) for the quart
HC Wainwright Has Positive Forecast for TRDA Q2 Earnings
Entrada Therapeutics, Inc. stock logo
What is HC Wainwright's Estimate for TRDA Q2 Earnings?
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2026 EPS estimates for Entrada Therapeutics in a research report issued to clients and investors on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju forecasts that the company
Entrada Therapeutics, Inc. stock logo
Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Northern Trust Corp lifted its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 28.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 318,177 shares of the company's stock af
Q2 Earnings Forecast for TRDA Issued By HC Wainwright
Entrada Therapeutics, Inc. stock logo
Entrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a report on Tuesday.
Entrada Therapeutics, Inc. stock logo
Janus Henderson Group PLC Acquires 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Janus Henderson Group PLC increased its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 21.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,080,367 shares of the company's sto
Entrada Therapeutics, Inc. stock logo
MPM Asset Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
MPM Asset Management LLC trimmed its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,381,062 shares of the comp
Entrada Therapeutics, Inc. stock logo
Q2 EPS Forecast for Entrada Therapeutics Reduced by Analyst
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Equities research analysts at Roth Capital lowered their Q2 2025 earnings per share estimates for Entrada Therapeutics in a report released on Sunday, May 11th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post
Entrada Therapeutics, Inc. stock logo
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 127.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 217,006 shares of the company's stock after pu
Q2 EPS Forecast for Entrada Therapeutics Lowered by Analyst
Entrada Therapeutics, Inc. stock logo
Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.36. The firm had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.
Entrada Therapeutics, Inc. stock logo
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Price T Rowe Associates Inc. MD
Price T Rowe Associates Inc. MD trimmed its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 4.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,903,025 shares of the company's stock
Entrada Therapeutics, Inc. stock logo
Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday
Entrada Therapeutics (NASDAQ:TRDA) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-entrada-therapeutics-inc-stock/)
Entrada Therapeutics, Inc. stock logo
Renaissance Technologies LLC Acquires 72,400 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Renaissance Technologies LLC increased its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 77.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 166,200 shares of the company's stoc
Entrada Therapeutics, Inc. stock logo
Vanguard Group Inc. Has $25.32 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Vanguard Group Inc. grew its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 19.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,464,237 shares of the company's stock after purchasing an addit
Entrada Therapeutics, Inc. stock logo
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Holdings Increased by Federated Hermes Inc.
Federated Hermes Inc. boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 3,104.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 99,814 shares of the company's stock after purchasing an additio
Entrada Therapeutics, Inc. stock logo
Arrowstreet Capital Limited Partnership Has $3.85 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Arrowstreet Capital Limited Partnership increased its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 123.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 222,520 shares of the company's st
Entrada Therapeutics, Inc. stock logo
HC Wainwright Issues Negative Estimate for TRDA Earnings
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Research analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for Entrada Therapeutics in a research note issued to investors on Monday, March 31st. HC Wainwright analyst R. Selvaraju now expects that the company wil
Entrada Therapeutics, Inc. stock logo
HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA)
HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Monday.
Entrada Therapeutics, Inc. stock logo
Connor Clark & Lunn Investment Management Ltd. Reduces Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Connor Clark & Lunn Investment Management Ltd. reduced its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 38.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 85,621 shares of the com
Entrada Therapeutics, Inc. stock logo
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday
Entrada Therapeutics (NASDAQ:TRDA) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports.
Entrada Therapeutics, Inc. stock logo
Analysts Set Expectations for TRDA Q4 Earnings
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at Roth Capital issued their Q4 2026 earnings estimates for shares of Entrada Therapeutics in a research report issued to clients and investors on Friday, February 28th. Roth Capital analyst B. Pachaiyappan expects that
Entrada Therapeutics, Inc. stock logo
What is William Blair's Estimate for TRDA Q1 Earnings?
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at William Blair issued their Q1 2026 EPS estimates for shares of Entrada Therapeutics in a report issued on Thursday, February 27th. William Blair analyst M. Minter anticipates that the company will earn ($0.73) per sha
Entrada Therapeutics, Inc. stock logo
Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.69 EPS
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.
Oppenheimer Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Entrada announces FDA removal of clinical hold on ENTR-601-44
Entrada Therapeutics Inc (TRDA) Receives a Buy from Roth MKM
Entrada Therapeutics, Inc. stock logo
Entrada Therapeutics (NASDAQ:TRDA) Receives "Buy" Rating from HC Wainwright
HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a research note on Tuesday.
Entrada receives authorization from UK MHRA to initiate ELEVATE-44-201
Roth MKM Sticks to Its Buy Rating for Entrada Therapeutics Inc (TRDA)
Get Entrada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.

TRDA Media Mentions By Week

TRDA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TRDA
News Sentiment

0.97

0.75

Average
Medical
News Sentiment

TRDA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TRDA Articles
This Week

14

2

TRDA Articles
Average Week

Get Entrada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:TRDA) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners